Danuglipron: Pfizer's Oral GLP-1 That Didn't Make It
Next-Gen Obesity Peptides
13% placebo-adjusted weight loss
Danuglipron's Phase 2b trial demonstrated competitive weight reduction, but tolerability and a liver safety signal ended the program before Phase 3.
Buckeridge et al., Diabetes, Obesity and Metabolism, 2025
Buckeridge et al., Diabetes, Obesity and Metabolism, 2025
View as imagePfizer spent years and billions of dollars developing danuglipron (PF-06882961), an orally bioavailable small-molecule agonist of the GLP-1 receptor, aiming to capture a share of the exploding weight loss drug market dominated by injectable peptides like semaglutide. The drug worked: Phase 2b data showed placebo-adjusted weight reductions of 8% to 13% at 32 weeks.[1] But three problems converged to kill the program. Gastrointestinal side effects drove dropout rates above 50%. A reformulation attempt to reduce dosing from twice to once daily ran into a potential drug-induced liver injury case. And the competitive landscape shifted under Pfizer's feet, with Eli Lilly's orforglipron posting stronger Phase 3 data with better tolerability.
In April 2025, Pfizer announced danuglipron's discontinuation. The molecule became one of the highest-profile casualties in the race for oral GLP-1 drugs, a category that remains one of the most commercially valuable frontiers in pharmaceutical development.
Key Takeaways
- Danuglipron's Phase 2b trial showed placebo-adjusted body weight reductions of 8% to 13% at 32 weeks with twice-daily dosing, comparable to injectable GLP-1 agonists[1]
- In a Phase 2 diabetes trial, danuglipron reduced HbA1c by 1.04% to 1.57% from baseline compared to 0.32% for placebo across dose groups[2]
- Gastrointestinal adverse events affected up to 73% (nausea) and 47% (vomiting) of participants, with discontinuation rates exceeding 50% at all doses[1]
- A single case of potential drug-induced liver injury in a dose-optimization study, combined with regulatory feedback, led Pfizer to terminate the program in April 2025
- A meta-analysis comparing danuglipron and orforglipron found both effective for glycemic control, but danuglipron carried higher odds of GI adverse events and treatment discontinuation[3]
- Danuglipron's failure highlights the challenge of converting a peptide drug's mechanism into a small-molecule format while preserving tolerability[4]
What Is Danuglipron?
Danuglipron is a non-peptide, small-molecule agonist of the human glucagon-like peptide-1 (GLP-1) receptor. Unlike injectable peptide GLP-1 agonists such as semaglutide and tirzepatide, danuglipron was designed to be taken as a pill. Sloop et al. (2024) detailed the pharmacological rationale: small molecules can activate the GLP-1 receptor through a binding site distinct from the orthosteric site used by peptide agonists, engaging the receptor's extracellular domain and transmembrane region in a way that triggers the same downstream signaling cascades (cAMP production, insulin secretion, appetite suppression) but through a structurally different interaction.[4]
The commercial logic was straightforward. Injectable GLP-1 drugs generated over $50 billion in 2024 revenue, but injection remains a barrier for many patients. An effective oral GLP-1 pill taken once or twice daily could dramatically expand the addressable market. Pfizer was not alone in pursuing this: Eli Lilly's orforglipron, AstraZeneca's MEDI7219, and several other candidates entered clinical development on the same thesis.
Danuglipron was Pfizer's entry in this race, identified through high-throughput screening and optimized through medicinal chemistry to achieve oral bioavailability, a half-life suitable for twice-daily dosing, and potent GLP-1R agonist activity.[5]
Phase 2 Trial in Type 2 Diabetes
Saxena et al. (2023) published a 12-week, randomized, placebo-controlled Phase 2 study evaluating danuglipron in adults with type 2 diabetes. The trial compared different dose-escalation schemes, testing whether slower titration could reduce the GI side effects that plagued earlier trials.[2]
The efficacy results were promising. Danuglipron reduced HbA1c by 1.04% to 1.57% across dose groups compared to 0.32% for placebo, with reductions in fasting plasma glucose of 23 to 54 mg/dL versus 13 mg/dL for placebo. Body weight also declined: participants lost 1.93 to 5.38 kg compared to 0.42 kg with placebo over 12 weeks.[2]
The tolerability data, however, revealed a problem that would define danuglipron's trajectory. Nausea affected 20% to 48% of participants across danuglipron groups versus 12.5% for placebo. Vomiting rates reached 18% to 41% versus 12.5% for placebo. Discontinuation from study medication occurred in 27% to 73% of participants across danuglipron groups versus 17% to 19% for placebo.[2]
Karakasis et al. (2023) conducted a systematic review and meta-analysis comparing danuglipron and orforglipron across published trials. Both drugs reduced HbA1c in patients with type 2 diabetes. But the safety analysis found that both oral GLP-1RAs had higher odds of gastrointestinal treatment-emergent adverse events and adverse events leading to discontinuation compared to placebo, with danuglipron showing a worse tolerability profile than orforglipron.[3]
Phase 2b Trial in Obesity: The Peak and the Problem
The Phase 2b obesity trial, published by Buckeridge et al. (2025) in Diabetes, Obesity and Metabolism, represented danuglipron's strongest efficacy data and, simultaneously, the clearest evidence of its tolerability ceiling.[1]
The study enrolled adults with obesity (BMI 30 or higher, or 27 with comorbidities) and randomized them to danuglipron at various twice-daily doses or placebo. At 32 weeks, placebo-adjusted mean body weight reductions ranged from 8% to 13%. At 26 weeks, reductions were 5% to 9.5%.[1]
These numbers placed danuglipron in competitive range with injectable GLP-1 agonists. For context, semaglutide 2.4 mg (Wegovy) produces approximately 15% weight loss at 68 weeks, and orforglipron produced 7.7% weight loss at 36 weeks in its Phase 2 NEJM trial.[6]
But the side effect and dropout data made these efficacy numbers practically uninterpretable. Up to 73% of participants experienced nausea. Up to 47% reported vomiting. Up to 25% had diarrhea. Most critically, discontinuation rates exceeded 50% across all danuglipron dose groups, compared to approximately 40% for placebo.[1]
When more than half of participants stop taking a drug, reported weight loss in the remaining patients is heavily selection-biased toward those who tolerated it. The people who stayed were not representative of the starting population. This makes it difficult to project what would happen in a real-world patient population.
Zhou et al. (2025) confirmed this pattern in a meta-analysis pooling danuglipron and orforglipron data across T2D and obesity studies. Both drugs showed efficacy, but danuglipron's safety profile was consistently worse, with higher rates of adverse events leading to treatment discontinuation.[7]
The Once-Daily Reformulation Attempt
Recognizing that twice-daily dosing was contributing to tolerability issues, Pfizer pursued a once-daily modified-release formulation. In December 2024, Pfizer reported that dose-optimization studies of the once-daily formulation met key pharmacokinetic objectives, achieving plasma levels predicted to deliver competitive efficacy with improved tolerability based on modeling from the twice-daily data.
For a brief period, this reformulation appeared to offer a path forward. Pfizer planned to advance the once-daily version into Phase 3 while abandoning the twice-daily formulation.
The Liver Signal and Program Termination
In April 2025, Pfizer announced the discontinuation of danuglipron's entire clinical program. The proximate trigger was a single asymptomatic case of potential drug-induced liver injury (DILI) in one of the dose-optimization studies. The participant's liver enzyme elevations resolved after stopping danuglipron.
Pfizer stated that the overall frequency of liver enzyme elevations across the 1,400+ participant safety database was in line with approved GLP-1 receptor agonists. But the DILI case, combined with "recent input from regulators" (likely the FDA), led Pfizer to conclude that the risk-benefit profile did not support continued development.
This decision reflected a broader calculus. A DILI signal in a weight loss drug intended for chronic use in otherwise healthy patients faces a much higher regulatory bar than the same signal in a cancer drug or last-resort therapy. With orforglipron and other competitors advancing without similar signals, regulators had little incentive to accept even a small liver risk from danuglipron.
Jaiswal et al. (2026) published a comprehensive characterization of danuglipron's metabolites, identifying both in vitro and in vivo metabolic pathways. This work provided a mechanistic basis for understanding danuglipron's hepatic processing, though it was published after the discontinuation decision.[8]
What Danuglipron's Failure Means for Oral GLP-1 Development
Danuglipron's discontinuation does not invalidate the oral small-molecule GLP-1 approach. It highlights specific challenges.
Tolerability is the gating factor. Efficacy in GLP-1 agonists is relatively easy to achieve: activate the receptor, reduce appetite, lose weight. The differentiator is how patients tolerate the treatment over months and years. Danuglipron's twice-daily dosing and rapid plasma peaks likely contributed to more intense nausea and vomiting than competitors with smoother pharmacokinetic profiles.
Small molecules activate the GLP-1R differently. Sloop et al. (2024) showed that non-peptide agonists bind to a site on the GLP-1R distinct from where peptide agonists bind.[4] This different binding mode can produce different signaling profiles, potentially explaining why some small molecules produce more GI effects than peptide agonists at equivalent levels of receptor activation.
The competitive bar keeps rising. When danuglipron entered clinical development, semaglutide was the benchmark. By the time of discontinuation, tirzepatide had shown 20%+ weight loss, CagriSema was combining semaglutide with an amylin analog, and orforglipron was posting cleaner Phase 3 data for an oral molecule. Danuglipron would have entered a market where its efficacy was average and its tolerability was below average.
Tolkacheva et al. (2025) reviewed the patent landscape for danuglipron-like and lotiglipron-like (Pfizer's backup molecule) GLP-1R agonists, noting that multiple pharmaceutical companies are pursuing structural analogs with improved pharmacokinetic profiles. The structural class remains active even after danuglipron's specific failure.[5]
Where Pfizer Goes Next
Pfizer has not exited the GLP-1/obesity space entirely. The company retains earlier-stage programs and has signaled interest in acquiring or licensing alternative approaches, including combination therapies targeting multiple metabolic pathways similar to dual and triple agonists being pursued by competitors. Whether Pfizer can recover its position in the obesity market after this setback remains an open question in the pharmaceutical industry.
The pharmaceutical industry's response to danuglipron's failure has been to diversify. Some companies are pursuing oral peptide formulations (like oral semaglutide) rather than small molecules. Others are combining GLP-1 activity with glucagon receptor agonism, as in pemvidutide, which targets liver fat alongside weight loss. The common thread is that single-mechanism, single-target approaches face diminishing returns in a market where combination strategies and differentiated safety profiles determine commercial success.
For the broader oral GLP-1 field, the key data to watch is orforglipron's Phase 3 program. If orforglipron succeeds where danuglipron failed, it will confirm that the oral small-molecule GLP-1 concept is viable but that execution, specifically the pharmacokinetic and tolerability profile, determines which molecules survive clinical development. Danuglipron's Phase 2b weight loss numbers prove the receptor can be activated orally; the question now is whether any company can do it with a side effect profile that patients will accept for years of chronic treatment.
The Bottom Line
Danuglipron demonstrated that an oral small molecule can activate the GLP-1 receptor and produce clinically meaningful weight loss (8-13% placebo-adjusted at 32 weeks) and glucose reduction (HbA1c reductions of 1.0-1.6%). Its failure was not one of efficacy but of tolerability: dropout rates exceeding 50%, GI side effects affecting up to 73% of participants, and a single case of potential drug-induced liver injury that, in the context of a crowded competitive field and regulatory caution, made continued development untenable. The molecule's history serves as a case study in how the race for oral GLP-1 drugs is won not by activating the receptor, but by doing so in a way patients can tolerate long-term.